Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

Heather Magnan, Christine M. Goodbody, Elyn Riedel, Christine A. Pratilas, Leonard H. Wexler, Alexander Ja-Ho Chou

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.

Original languageEnglish (US)
Pages (from-to)594-597
Number of pages4
JournalPediatric Blood and Cancer
Volume62
Issue number4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Ifosfamide
Ewing's Sarcoma
Survival
Poisons
Disease-Free Survival
Disease Progression
Leukemia
Drug Therapy

Keywords

  • Chemotherapy
  • Ewing sarcoma
  • Outcomes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Magnan, H., Goodbody, C. M., Riedel, E., Pratilas, C. A., Wexler, L. H., & Chou, A. J-H. (2015). Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. Pediatric Blood and Cancer, 62(4), 594-597. https://doi.org/10.1002/pbc.25373

Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. / Magnan, Heather; Goodbody, Christine M.; Riedel, Elyn; Pratilas, Christine A.; Wexler, Leonard H.; Chou, Alexander Ja-Ho.

In: Pediatric Blood and Cancer, Vol. 62, No. 4, 01.01.2015, p. 594-597.

Research output: Contribution to journalArticle

Magnan, H, Goodbody, CM, Riedel, E, Pratilas, CA, Wexler, LH & Chou, AJ-H 2015, 'Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma', Pediatric Blood and Cancer, vol. 62, no. 4, pp. 594-597. https://doi.org/10.1002/pbc.25373
Magnan, Heather ; Goodbody, Christine M. ; Riedel, Elyn ; Pratilas, Christine A. ; Wexler, Leonard H. ; Chou, Alexander Ja-Ho. / Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. In: Pediatric Blood and Cancer. 2015 ; Vol. 62, No. 4. pp. 594-597.
@article{140908cecc7544bd8c7e72729f4e4e6b,
title = "Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma",
abstract = "Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC {"}EFT regimen.{"} The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27{\%} and the overall survival (OS) was 39{\%}. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.",
keywords = "Chemotherapy, Ewing sarcoma, Outcomes",
author = "Heather Magnan and Goodbody, {Christine M.} and Elyn Riedel and Pratilas, {Christine A.} and Wexler, {Leonard H.} and Chou, {Alexander Ja-Ho}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/pbc.25373",
language = "English (US)",
volume = "62",
pages = "594--597",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

AU - Magnan, Heather

AU - Goodbody, Christine M.

AU - Riedel, Elyn

AU - Pratilas, Christine A.

AU - Wexler, Leonard H.

AU - Chou, Alexander Ja-Ho

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.

AB - Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.

KW - Chemotherapy

KW - Ewing sarcoma

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84923222093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923222093&partnerID=8YFLogxK

U2 - 10.1002/pbc.25373

DO - 10.1002/pbc.25373

M3 - Article

C2 - 25630954

AN - SCOPUS:84923222093

VL - 62

SP - 594

EP - 597

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -